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RESUMO 
 
 O gene PAX9, pertencente à família Pax, é amplamente expresso em vários tecidos 
craniofaciais durante o desenvolvimento. Sabe-se que mutações neste gene em humanos 
causam fenótipo de oligodontia, afetando os dentes molares e segundos pré-molares. 
Grande variedade de agentes fisiológicos e farmacológicos externos podem ter impacto 
relevante na regulação da atividade transcricional de genes modulando fatores de 
transcrição.  A presente tese focaliza o estudo da região 5´do gene PAX9 humano e tem 
como objetivo analisar a influência da dexametasona, ácido retinóico e ergocalciferol 
(vitamina D2) na atividade transcricional de sua região promotora, utilizando construções 
em vetor plasmideano que dirige a transcrição do gene da luciferase de vagalume (Photinus 
pyralis, pGL3 basic vector). Para ensaios de transcrição, foram amplificados através de 
ensaios com transcriptase reversa, transcritos do gene PAX9 de células mamárias de 
adenocarcinoma MCF-7 e células odontoblastóides de camundongo MDPC23. Estes 
transcritos foram quantificados através de PCR quantitativo. Fragmentos da região 
promotora do gene PAX9 humano de 1198pb (−1106 - +92), 843pb (−751- +92) e 691bp 
(−1106 - +92 com deleção de 507pb nos sítios -645 e -138) foram recombinados com vetor 
de expressão pGL3Basic e denominados PAX9-pGL3B1, PAX9-pGL3B2 e PAX9-pGL3B3, 
respectivamente. As contruções foram transfectadas em cultura de células mamárias de 
adenocarcinoma MCF-7 e células odontoblastóides de camundongo MDPC23. Todas as 
placas de cultura foram submetidas à ação de três drogas: dexametasona (DEX), ácido 
retinóico (RE) e ergocalciferol (VITD2). Após lise das células, os níveis relativos de 
expressão da proteína luciferase foram analisados com o uso do kit Dual-Glo Luciferase em 
luminômetro. Os resultados referentes às células mamárias de adenocarcinoma MCF-7 
mostraram que: 1) Altas concentrações de ácido retinóico aumentaram a síntese de RNA 
mensageiro transcrito. 2) Fragmentos do promotor PAX9 de 1198pb (PAX9-pGL3B1) e 
843pb (PAX9-pGL3B2) foram ativados na presença de ácido retinóico mas suas 
transcrições desestimuladas na presença da dexametasona e ergocalciferol. 3) A atividade 
da luciferase na construção PAX9-pGL3B2 foi mais fraca que outras duas construções, 
indicando que a sequência -1106 and -751 ou 355pb era importante para a atividade 
transcricional. 4) Fragmento do promotor clivado nos sítios -645 e -138 com deleção de 
507pb (PAX9-pGL3B3) foi ativado negativamente somente na presença do ergocaciferol, 
 viii 
enquanto que com a dexametasona e ácido retinóico o mesmo não foi afetado. Quanto às 
células odontoblastóides de camundongo MDPC23, os resultados mostraram que: 1) Todas 
as concentrações de ergocalciferol influenciaram positivamente a síntese de RNA 
mensageiro transcrito. 2) A atividade promotora das construções PAX9-pGL3B1 e PAX9-
pGL3B2 foi aumentada com baixa concentração de dexametasona e ergocaciferol enquanto 
que alta concentração diminuiu esta atividade. 3) Na construção PAX9-pGL3B3, todas 
concentrações de ergocaciferol influenciaram a transcrição do promotor negativamente, 
enquanto que com a dexametasona e ácido retinóico, a mesma não foi afetada. Concluímos 
que as drogas dexametasona, ácido retinóico e ergocalciferol podem modular a expressão 
do gene PAX9. A região de 507pb deletada do promotor do gene PAX9 humano pode conter 
sítios de ligação para receptores do ácido retinóico e dexametasona.  
 
Palavras Chaves: Região promotora do gene PAX9, atividade de transfecção, ensaios de 
luciferase, pGL3 Basic Vector.  
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ABSTRACT 
  
PAX9, member of the family homeobox, has important functions in embryogenesis 
and it is widely expressed in various craniofacial tissues during development. PAX9 
mutations in human families cause autosomal dominant oligodontia, characterized by the 
absence of permanent molars and pre-molars. A great variety of physiological or 
pharmacological environmental factors may have impact on downstream signaling cascades 
and transcriptional regulation of gene modulating transcription factors. This work focused 
on the analysis on the 5’-flanking region of the PAX9 gene studying the influence of 
retinoic acid, dexamethasone and vitamin D on the expression of PAX9 by expression 
constructs that carry the reporter gene luciferase (Photinus pyralis, pGL3 basic vector). In 
the present study, we have PCR amplified cDNAs encoding mouse Pax9 from Mouse 
Odontoblast Cell-Like-23 (MDPC23) and PAX9 from Human breast adenocarcinoma 
(MCF-7) and quantified by Quantitative PCR. We examined the transcriptional activity of 
human PAX9 promoter from constructions: 1) PAX9-pGL3B1 construct clone PAX9 gene 
promoter 1198bp from −1106 upstream to +92 downstream of translation start site (ATG). 
2) PAX9-pGL3B2 construct clone PAX9 gene promoter 843bp from −751 upstream of 
translation start site (ATG) to +92 downstream of translation start site (ATG). 3) PAX9-
pGLB3 construct clone PAX9 gene promoter 691bp from −1106 upstream of translation 
start site (ATG) to +92 downstream of translation start site (ATG) using deletion of 507bp 
in restriction sites (-645 and -138) of ApaI enzyme. These constructions were transfected 
into Mouse Odontoblast Cell-Like-23 (MDPC23) and PAX9 from Human breast 
adenocarcinoma (MCF-7). Cell cultures were all submitted to selective regulation of tree 
drugs: dexamethasone (DEX), retinoic acid (RE) and ergocalciferol (VITD2). Relative 
luciferase expression units were obtained by dual luciferase assay kit. The results in Human 
breast adenocarcinoma (MCF-7) showed that retinoic acid and dexamethasone influenced 
negatively the expression of PAX9 promoter. PAX9-pGL3B1 and PAX9-pGL3B2 promoter 
was inhibited under the treatment of dexamethasone and ergocalciferol. Retinoic acid and 
dexamethasone did not altered PAX9-pGL3B3 (−1106 to +92, 507bp deleted with ApaI 
digest) behavior. Luciferase activity in plasmid PAX9-pGL3B2 was always weaker than the 
other two constructions indicating that sequence present between -1106 and -751 or 355bp 
 x 
were important for the transcriptional activity of PAX9 promoter. The results in Mouse 
Odontoblast Cell-Like-23 (MDPC23) showed that it PAX9-pGL3B1 and PAX9-pGL3B2 
promoter activity was increased by the treatment of lower concentration of dexamethasone 
and ergocalciferol, whereas higher concentration of the same drugs decreased this activity. 
The effect of the retinoic acid in the luciferase activity of PAX9-pGL3B1 has the same 
pattern but for the PAX9-pGL3B2, all concentrations increased the promoter activity. For 
the PAX9-pGL3B3 construction, concentrations of ergocalciferol had a statistically 
significance decreasing the activity of the promoter and no effect of the activity was 
observed in the dexamethasone and retinoic acid treatment. In conclusion, dexamethasone, 
retinoic acid and ergocalciferol may bind to PAX9 gene promoter and up or down-regulate 
PAX9 transcriptional activity. A 507bp region (-645 and -138) within PAX9 promoter may 
harbor biding sites for dexamethasone and retinoic acid since none of concentrations of 
these reagents influenced changes in promoter activity.  
 
Key words: PAX9 promoter gene, transcriptional activity, luciferase assays, pGL3 Basic 
Vector. 
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INTRODUÇÃO 
 
 Os genes da família homeobox são conhecidos por desempenhar papéis importantes 
nas interações indutivas dos tecidos, amplamente expresso em vários tecidos craniofaciais 
durante o desenvolvimento funcionando como fatores de transcrição durante a 
organogênese dos vertebrados (Vainio S. et al. 1993). O gene PAX9, o nono membro 
pertencente à família de fatores de transcrição Pax, participa como regulador da 
embriogênese e desenvolvimento dos vertebrados sendo amplamente expresso em vários 
tecidos craniofaciais durante o desenvolvimento e funciona como iniciadores da 
diferenciação celular e mantendo a pluripotência de células em desenvolvimento (Gruss P. 
et al. 1992). Acredita-se que o Pax9 desempenhe também uma função essencial no 
desenvolvimento do germe dental, sendo expresso nas fases de iniciação, botão, capuz, e 
estágio de sino da odontogênese (Thesleff, 2003, Kapadia et al., 2007 Neubüser A. 1995, 
Peters et al. 1998, Peters et al. 1999).  
Mutações no gene Pax9 foram reportadas em famílias com um padrão autossômico 
dominante de agenesia dental afetando principalmente segundos pré-molares e terceiros 
molares (Vastardis et al 1996, Van den Boogaard 2000). Outras mutações no PAX9 também 
foram associadas com a agenesia dental em humanos, afetando principalmente segundos 
pré-molares e todos os molares. Também nestes casos as alterações eram transmitidas como 
um padrão autossômico dominante (Stockton et al. 2000, Nieminen et al. 2001; Frasier-
Bowers et al. 2002; Das et al. 2002; Das et al. 2003; Mostowska et al. 2003, Jumlongras et 
al. 2004). Polimorfismos na região 5´ do gene PAX9 parecem estar associados com a 
hipodontia em humanos (Peres et al. 2005). É interessante notar que enquanto a agenesia 
dental foi a principal (na maioria dos casos a única) alteração observada nas famílias com 
mutação nos genes PAX9, a mutação deste gene em camundongo foi acompanhada por 
múltiplas alterações craniofaciais incluindo agenesia de todos os dentes (Satokata e Maas 
1994, Peters et al. 1998). Apesar de serem produzidos em vários tecidos durante a 
embriogênese a mutação dos dois alelos dos genes Pax9 afeta principalmente o 
desenvolvimento craniofacial.  
 Acredita-se que a expressão proteica é principalmente regulada durante a 
transcrição (Veitia et al. 2006, Tomilin et al. 2008, Celniker et al. 2007). Neste processo, a 
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região promotora possui um papel fundamental mudando a expressão gênica devido seu 
potencial de incorporar sinais endócrinos e ambientais (Vlahopoulos S et al. 2004). Grande 
variedade de agentes fisiológicos e farmacológicos externos podem ter um impacto 
relevante na regulação da atividade transcricional de genes modulando variada classe de 
fatores de transcrição.  Drogas podem se ligar diretamente ou indiretamente modular classe 
de receptors nucleares de fatores de transcrição através de cascatas de sinalização como, 
por exemplo, o tamoxifen utilizado no tratamento de cancer de mama e vários outros tipos 
de anti-inflamatórios e hormônios esteróides (Overington et al., 2006).  
 Pouco se conhece sobre a atividade transcricional do gene PAX9 humano. Para 
elucidarmos nosso conhecimento sobre sua regulação, o presente trabalho focaliza o estudo 
da região 5´do gene PAX9 humano e tem como objetivo analisar a influência da 
dexametasona, ácido retinóico e ergocalciferol (vitamina D2) na atividade transcricional de 
sua região promotora, utilizando construções em vetor plasmideano que dirige a transcrição 
do gene da luciferase de vagalume (Photinus pyralis, pGL3 basic vector). 
 Transcritos do gene PAX9 de células mamárias de adenocarcinoma MCF-7 
(Human breast adenocarcinoma) e células odontoblastóides de camundongo MDPC23 
(Mouse Odontoblast Cell-Like-23) foram amplificados através de ensaios com transcriptase 
reversa nos ensaios de transcrição. Para a análise da atividade transcricional da região 
promotora do gene PAX9, a região promotora inteira ou fragmentos menores obtidos com 
deleção através de restrição com enzima ApaI, foram recombinadas ao vetor de expressão 
pGL3Basic. Sob influência de drogas que notoriamente influenciam na transcrição de 
alguns genes, dexametasona, ácido retinóico e ergocalciferol (vitamina D2), células 
mamárias de adenocarcinoma MCF-7 (Human breast adenocarcinoma) e células 
odontoblastóides de camundongo MDPC23 (Mouse Odontoblast Cell-Like-23) sofreram 
transfecção com os recombinantes citados acima, com finalidade de avaliar o 
comportamento transcricional destes frente à ação das drogas. 
 A análise da expressão de transcritos de cDNA provenientes da cultura de células 
mamárias de adenocarcinoma MCF-7 (Human breast adenocarcinoma) e células 
odontoblastóides de camundongo MDPC23 (Mouse Odontoblast Cell-Like-23) através de 
reação de PCR Quantitativo forneceu dados complementares sobre o padrão de expressão 
gênica do PAX9 sob a ação da dexametasona, ácido retinóico e ergocalciferol. O estudo 
 3 
realizado visa contribuir para o melhor entendimento da atividade transcricional do gene 
PAX9 humano. 
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ABSTRACT 
 
PAX9 is a member of the family homeobox of transcription factors and performs 
important functions in development and organogenesis. Mutations in PAX9 coding 
sequences have been implicated in autosomal dominant oligodontia affecting 
predominantly permanent molars and second premolars. Previous studies have shown that 
PAX9 is required for secondary palate development and certain teratogens have been 
identified as inducers of a tooth and craniofacial malformations. This work focused on the 
analysis on the 5’-flanking region of the PAX9 gene studying the influence of retinoic acid, 
dexamethasone and vitamin D on the expression of PAX9 by expression constructs that 
carry the reporter gene luciferase. As results, retinoic acid and dexamethasone showed 
progressive decrease of PAX9 expression. PAX9-pGL3B1 and PAX9-pGL3B2 promoter 
was inhibited under the treatment of dexamethasone and ergocalciferol. Retinoic acid and 
dexamethasone did not altered PAX9-pGL3B3 (−1106 to +92, 507bp deleted with ApaI 
digest) behavior. Luciferase activity in plasmid PAX9-pGL3B2 was always weaker than the 
other two constructions indicating that sequences present between -1106 and -751 were 
important for the transcriptional activity of PAX9 promoter.  
 
 
Keywords: PAX9 promoter gene, transcriptional activity, pGL3 Basic Vector, Luciferase 
Assays, Human breast adenocarcinoma MCF-7 cells. 
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INTRODUCTION 
 
 PAX9 (14q12-q13) is ninth member of highly conserved Pax homeobox family of 
transcription factors that play an active role in vertebrate development (Stapleton et al., 
1993; Wallin et al., 1993). PAX9 expression displays a spatially and temporally restricted 
pattern in various embryonic tissues including the somites, the distal limb buds, nasal 
mesenchyme, the mandibulary and maxillary components of the first branchial arch and the 
tongue mesenchyme, suggesting a critical role in morphogenesis (Neubüser et al. 1997). 
Targeted inactivation in mouse embryo has shown that Pax9 is required for the proper 
development of pharyngeal pouch derivatives, the craniofacial skeleton, palate, digits and 
teeth, where it is expressed in the initiation, bud, cap, bell stages of odontogenesis 
(Thesleff, 2003, Kapadia et al., 2007, Neubüser A. 1995, Peters et al. 1998, Peters et al. 
1999). PAX9 mutations in human families cause autosomal dominant oligodontia, 
characterized by the absence of permanent molars and pre-molars (Goldenberg et al. 2000, 
Stockton et al. 2000, Nieminen et al. 2001). It is interesting to note that ablation of both 
alleles in knockout mice is accompanied by many craniofacial alterations (Satokata and 
Maas 1994, Peters et al. 1998).  Dental agenesis was the main (in most cases the only) 
change observed in families with mutations in PAX9 gene.  
 It is believed that protein expression is mainly regulated during transcription 
(Veitia et al. 2006, Tomilin et al. 2008, Celniker et al. 2007). In this process, the promoter 
region has a key role in changing gene expression due to its potential to incorporate 
endocrine and environmental signals (Vlahopoulos S et al. 2004). A great variety of 
physiological or pharmacological environmental factors may have impact on downstream 
signaling cascades and transcriptional regulation of gene since they may bind to promoter 
region. Drugs may directly target and indirectly modulate the nuclear receptor class of 
transcription factors through signaling cascades such as tamoxifen for the treatment of 
breast cancer and various types of anti-inflammatory and anabolic steroids (Overington et 
al., 2006).  
 Little is known about transcriptional regulation of human PAX9 gene. In order to 
broaden our knowledge on PAX9 expression, the aim of this work was to determine 
whether dexamethasone (DEX), retinoic acid (RE) and ergocalciferol (VITD2) treatment 
may change the expression of PAX9 and to evaluate if these drugs can interfere with the 
transcriptional activity of this gene. 
 
MATERIALS AND METHODS 
 
DNA extraction and amplification 
 
Genomic DNA from healthy patients was extracted from samples of epithelial oral 
cells collected by mouthwash with dextrose 3% and purified using 8M ammonium acetate 
and 1mM EDTA (Aidar & Line 2007).  Sequences between positions -1106 to +92 and -
751 a +92 were amplified by PCR using primers PAX9 SacI-HindIII and PAX9 KpnI-
HindIII, respectively, designed with Primer3 version 0.2 (Massachusetts Institute of 
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Technology, Boston, MA) (Table 1). PCR reactions were performed in a total volume of 25 
μl containing 20 ng/2 μl genomic DNA, 10 pg of each primer, 2.5 μl MgCl2 (25 mM), 2.0 
μl dNTP mixture (2.5 mM each), 2.5 μl of 10× reaction buffer and 0.2–0.4 unit of 
thermostable DNA polymerase. DNA was denaturated at 95°C for 2 min, followed by 35 
cycles of denaturation of 30s at 95°C, annealing for 45s at 60–64°C, extension of 45–60s at 
72°C, and final extension of 10 min at 72°C on GeneAmp 2400 PCR Thermal Cycler (ABI 
corporations). Aliquots (5μl) of the PCR product were electrophoresed on 1% agarose gels 
and visualized under UV illumination after staining with ethidium bromide.  
 
Generation of promoter constructs 
 
 The PCR products of 1198 bp and 843 bp containing the 5’-flanking region of 
PAX9 gene was generated from human genomic DNA obtained from oral epithelial cells of 
a healthy individual. The PCR products were cloned in the luciferase reporter plasmid using 
the vector pGL3 Basic. Luciferase reporter recombinant PAX9-pGL3B1 and PAX9-
pGL3B2 were generated by inserting the promoter fragment into SacI-HindIII and KpnI-
HindIII sites of pGL3-Basic vector, respectively. The luciferase reporter recombinant 
PAX9-pGLB3 was generated by deleting 507bp from the 1198bp promoter fragment 
already cloned in the vector pGL3-basic using ApaI restriction enzyme. Constructs were 
confirmed by DNA sequencing, restriction enzymes digest with SacI, KpnI, HindIII 
combined and PCR. The pRL-TK vector (Promega) containing the reporter Renilla 
luciferase gene was used as a control to correct variations in transfection efficiency. The 
constructs are shown in Figure 1. 
 
 
 
Fragment Forward primer (5´ - 3´) Reverse primer (5´- 3´) Product 
Size 
PAX9 SacI-
HindIII  
CTCGAGGTGTAGAGCTCGCAGC AAGCTTCTAGGTGATTGGTGCGGGTCGGT 1198bp 
PAX9 KpnI-
HindIII 
TCTGGATTGTCAGGTACCAGTAACAG   AAGCTTCTAGGTGATTGGTGCGGGTCGGT 843bp 
Table 1. Primers used to amplify regions PAX9 gene promoter. Restriction sites of 
enzymes SacI, KpnI and Hind III in italic. 
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Figure 1. Schematic diagram of promoter constructs. 1) PAX9-pGL3B1 construct clone 
PAX9 gene promoter 1198bp from −1106 upstream to +92 downstream of translation start 
site (ATG). 2) PAX9-pGL3B2 construct clone PAX9 gene promoter 843bp from −751 
upstream of translation start site (ATG) to +92 downstream of translation start site (ATG). 
3) PAX9-pGLB3 construct clone PAX9 gene promoter 691bp from −1106 upstream of 
translation start site (ATG) to +92 downstream of translation start site (ATG) using deletion 
of 507bp in restriction sites (-645 and -138) of ApaI enzyme.  
 
DNA sequencing 
 
In order to confirm cloning assays, samples of constructions were subjected to 
automatic sequencing in 20 μl containing 1 μl of DNA, 3 μM of sense primer and 8 μl of 
Big Dye Terminator Ready v.2.0 (Applied Biosystems, Foster city, CA, USA). The cycle 
sequencing product was then run through an ABI 3739 automated sequencer (Perkin Elmer, 
Applied Biosystems, USA) according to the manufacturer´s protocol. The screening of the 
sequence was performed by comparing the output nucleotide sequence with published 
sequence of the PAX9 gene (GenBank database) using Clustawl and naked eye check by 
Bioedit sequence alignment Editor Software /version 7.0.5.3. The potential cis-acting factor 
biding sites were predicted by the MatIsnpector software (www.genomatix.de).  
 
 
 
Culture cells and drug treatments 
 
 Human breast adenocarcinoma MCF-7 cells were generously provided by Dr. 
Zoltan Tokes, University of Southern California (Los Angeles, CA) and cultured according 
 9 
to the suppliers protocol at 37°C humidified atmosphere, 5% CO2 in DMEM (Invitrogen, 
Carlsbad, CA) media supplemented with 5% fetal bovine serum (Invitrogen, Carlsbad, 
CA), 1% penicillin/streptomycin (Invitrogen, Carlsbad, CA) and 1% GlutaMax (Invitrogen, 
Carlsbad, CA). Unless otherwise stated, cells were plated at 500,000 cells/10 cm plate. The 
medium was replaced every 2–3 days. The mycoplasma test was performed using 
MycoAlert
®
 Mycoplasma Detection Kit (Lonza).  
  
Chemicals 
 
Dexamethasone (9α-Fluoro-16α methylprednisolone - DEX), All-trans-Retinoic 
acid - RE (Tretinoin) and Ergocalciferol (Irradiated ergosterol/Vitamin D2 - VITD2) (St. 
Louis, MO, USA) was diluted in ethanol at final concentration of 10mM as stock solution. 
Approximately 5 x 10
4
 to 1 x 10
5
 MCF-7 cells was maintained in 12-well culture plates and 
exposed in triplicate to reagents at concentrations of 0.1 μg/ml, 1μg/ml, or 10μg/ml, to 
ethanol 100% (vehicle control added to untreated samples) 48 hrs prior to mRNA 
extraction, according to conditions previously described (Antonova L. and Mueller C. 
2008). 
 
Reverse transcription and Real-time PCR 
 
Total RNA was harvested from cells and purified using the Aurum Total RNA mini 
kit (BioRad), following the manufacturer’s recommendation. cDNA was synthesized from 
3μg total RNA using the High capacity archive cDNA kit (Applied Biosystems, Carlsbad, 
CA). Real-time PCR was performed on the 7900 Fast RealTime PCR machine (Applied 
Biosystems, Carlsbad, CA) and TaqMan Assay kits (Applied Biosystems, Carlsbad, CA) 
that include primers and FAM-labeled probe sets specifically targeting human PAX9 gene 
and TATA box binding protein gene. Real-time PCR was conducted using standardized 
conditions with a 60°C annealing temperature for 30s. All primers used were validated 
realtime PCR primers purchased from Applied Biosystems (Carlsbad, CA).  
 
Transient transfections and Dual luciferase assay system 
 
MCF-7 cells (3x10
5
cells/well) were plated in 12-well plates
 
(Becton Dickinson, San 
Jose, CA, USA) and incubated for 3 days. On the third day (cells reached 80%-90% of 
confluence), the culture medium was aspirated, and the cell monolayer was washed with 
pre-warmed sterile PBS and trypsinazed with 1x Trypsin-EDTA (0.05% trypsin/0.02% 
EDTA) (Invitrogen, Carlsbad, CA). Cells were tranfected by eletroporation using Electro 
Square Porator ECM830 (BTX, CA) according to the manufacturer’s instructions (240V 
with a single 25-ms pulse) with 4000ng of pGL3-basic promoter construct PAX9-pGL3B1, 
PAX9-pGL3B2 and PAX9-pGL3B3 encoding a firefly luciferase gene (pGL3-basic vector) 
and co-transfected with 300ng of pRL-TK (Promega, USA) encoding the Renilla luciferase 
gene. Cells were kept under triplicate treatment of concentrations of 10μg/ml, 1μg/ml and 
0μg/ml for each reagent (Dexamethasone, Retinoic acid and Ergocalciferol) for 48 hours. 
Then cells were lysed with the passive lysis
 
buffer (Promega, Madison, WI) and assayed in 
triplicate for luciferase activity on a 1420 Multilabel Counter Victor
3
 V plate reader 
(Perkin-Elmer, Turku, Finland) using the Dual-Luciferase Assay System (Promega) 
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according to the manufacturer’s instructions. Promoter activities were expressed as a ratio 
of firefly luciferase to Renilla luciferase luminescence in each well.  
 
Trypan blue assays 
 
Cell viability was determined by trypan blue assays testing whether dexamethasone, 
retinoic acid and ergocalciferol challenged cells. Trypan blue assays exclusion test 
challenged cells were performed as previously described by Lissy 2000 and Devireddy 
2001. In brief, cells were harvested by brief trypsinization 24 h after the addition of 
Dexamethasone, Retinoic Acid and Ergocalciferol (Sigma). Both floating and attached cells 
were assayed. At least 150 cells per treatment were counted after being stained with trypan 
blue at a final concentration of 0.2%. Assays were performed in duplicate in tree 
independent experiments. 
 
Statistical analysis 
 
With respect to Real-time PCR PAX9 gene expression analysis, an inter-group 
analysis was performed using nonparametric Kruskal–Wallis test at the level of 5%, 
followed by Dunn’s test when differences were detected. Sample means and standard 
deviations were calculated for the luciferase assays which were performed in triplicate. 
Individual experiments were carried out at least three times and a representative experiment 
is shown. Statistical analysis calculations for luciferase assay results were performed using 
the two-sample Student’s t-test function assuming equal variances. The values of P ≤ 0.05 
were regarded as significant. 
 
RESULTS 
 
PAX9 mRNA expression in MCF-7 under DEX, RE and VITD2 treatment 
  
In order to assess the effect of various drugs on PAX9 expression in MCF-7 cells, 
cells were treated with various concentrations of dexamethasone, retinoic acid and 
ergocalciferol for 48 hours. Dexamethasone did not affect PAX9 mRNA synthesis in MCF-
7 cells. In the same culture conditions, 0.1μg/ml, 0.1μg/ml 10μg/ml of retinoic acid 
increased PAX9 mRNA expression in 3, 5 and 7%, respectively when compared with 
untreated cells (p≤0.001) (Figure 2). 
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Figure 2. The influence of various concentrations of Dexamethasone (DEX), Retinoic Acid 
(RE) and Ergocalciferol (VITD2) in MCF-7 breast cancer cells. Exposure time 48hrs. 
Control=100% ethanol. Data presented as mean values ± SD (n=3). *p≤0.001. 
 
PAX9-pGL3B1, PAX9-pGL3B2 and PAX9-pGL3B3 construct confirmation 
 
 In total, we combined tree specific sequences of the promoter region of human 
PAX9 gene with the pGL3-basic vector encoding a firefly luciferase gene (PAX9-pGL3B1 - 
from −1106 to +92, PAX9-pGL3B2 - from −751 to +92 and PAX9-pGLB3 - from −1106 to 
+92 with deletion of 507bp), which were confirmed by sequencing, restriction enzyme 
cutting and PCR (Figure 3A and 3B). 
 
 
Figure 3.  PAX9-pGL3B1 and PAX9-pGL3B2 construct confirmation by restriction 
enzymes digest and PCR - gel electrophoresis. A) M: Marker 100bp; A1, A2 and A3: PCR 
product of PAX9-pGL3B1, PAX9-pGL3B2 and PAX9-pGL3B3 constructs respectively 
(primers on table 1). B) 3B) pGL3-Basic; 2B) pGL3-Basic single cut with KpnI; 1B) 
Recombinant PAX9-pGL3B2 construct confirmed by cut with KpnI and HindIII. 
 
Transcriptional activity of PAX9 promoter in MCF-7 under DEX, RE and VITD2 treatment  
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To examine the transcriptional activity of the PAX9 gene promoter, 1198bp 
fragment        (-1106 to +92), 843bp (-751 to +92) and 691bp (deletion of 507bp from 
region -1106 to +92) was placed in the upstream of the firefly luciferase gene in the pGL3-
Basic vector. The resultant plasmid PAX9-pGL3B1, PAX9-pGL3B2 and PAX9-pGL3B3 
was transiently transfected into the MCF-7 cells that were treated with various 
concentrations of dexamethasone - DEX, retinoic acid – RE and ergocalciferol – VITD2 for 
48 hours. Then, the firefly luciferase activity obtained was compared with those from the 
pRL-TK-control plasmid. Treatment with 10μg/ml of dexamethasone decreased luciferase 
activity to 47% and 82% in PAX9-pGL3B1 and PAX9-pGL3B2, respectively (p≤0.003, 
figure 4A).  
The same effect of downregulation in luciferase activity was observed with 
ergocalciferol treatment of PAX9-pGL3B1, PAX9-pGL3B2 and PAX9-pGL3B3. There was 
a 28% decrease with 1μg/ml and 37% with 10μg/ml for PAX9-pGL3B1 (p≤0.002). For 
plasmid PAX9-pGL3B2, there was a 29% decrease in luciferase activity with 1μg/ml, and 
65% with 10μg/ml (p≤0.002) (figure 4C). For plasmid PAX9-pGL3B3, the decrease in 
luciferase activity for concentrations of 10μg/ml and 1μg/ml were 34% and 26%, 
respectively.  
Conversely, 1μg/ml of Retinoic acid increased luciferase activity in 73% for PAX9-
pGL3B1 and 267% for PAX9-pGL3B2 construction (p≤0.002) (figure 4B).  
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Figure 4. Functional analysis of PAX9 gene promoter by the Dual luciferase assay in MCF-
7 cells. Luciferase activity in MCF-7 cells transfected with PAX9-pGL3B1, PAX9-
pGL3B2, PAX9-pGL3B3 and pRL-TK as a control under Dexamethasone (DEX) (4A), 
Retinoic Acid (RE) (4B) and Ergocalciferol (VITD2) (4C) treatment. 
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DISCUSSION 
 
We have shown in time and concentration dependent manner that retinoic acid 
increases expression activity of PAX9 gene in MCF-7 cancer cells on RT-PCR experiment. 
It is known that retinoic acid receptors act as transcription factors regulating gene 
expression/protein production (Balmer and Blomhoff 2002). Besides, more than 532 genes 
have been put forward as regulatory targets of retinoic acid (Blalock and Gifford 1977). It 
is also has been reported that PAX9 is required for secondary palate development and 
certain teratogens such as retinoic acid have been identified as inducers of cleft secondary 
palate (Sulik et al. 1988, Gorlin et al. 1990, Peters et al. 1998). In early developmental 
stages retinoic acid receptors act directly in the regulatory regions and transcription of 
homeobox genes targets controlling anterior/posterior patterning (Holland LZ. 2007). Our 
study are in agreement with previous works confirming that genes containing homeobox 
domains are among the various types of genes regulated directly through the classical 
Retinoic acid pathway (Balmer and Blomhoff 2002), thereby activating PAX9 gene 
transcription directly. However, no significant changes in PAX9 expression were found in 
RT-PCR analysis with dexamethasone and ergocalciferol treatment. 
We found with dual luciferase promoter function assay that lower concentration of 
retinoic acid activates PAX9-pGL3B1 (−1106 to +92) and PAX9-pGL3B2 (−751 to +92) 
luciferase if compared with ethanol group alone. It is interesting to observe that the 
influence of retinoic acid was different when comparing RT-PCR and Luciferase assays. 
Retinoic acid increased the expression of PAX9 mRNA, while the same concentration 
decreased expression in the luciferase assays. This may be explained because the 
transcriptional activity of the PAX9 gene may be influenced by other sequences distant 
from transcription start site. In fact, cis-regulatory sequences of Pax9 gene were identified 
in intronic sequences of the neighboring gene Slc25a21 (Santagati et al 2003).  
Different from PAX9-pGL3B1 and PAX9-pGL3B2 constructions, retinoic acid and 
dexamethasone did not alter luciferase activity in PAX9-pGL3B3 (−1106 to +92, 507bp 
deleted with ApaI digest). This result suggests that 507bp deletion or -645 to -138 of this 
construction may contain biding sites for retinoic acid and dexamethasone receptors or 
other transcription factors, whose expression is modulated by these drugs. The analysis of 
the DNA biding sites on MatInspector software (http://www.genomatix.de/cgi-
bin/eldorado/main.pl) revealed that the region of 507bp deleted in the construction PAX9-
pGL3B3 has around 85 transcriptional biding motifs that may be sites for signaling cascade 
proteins initially activated by the presence of extracellular retinoic acid. This region of 
507bp is located within various core binding sequences, such as, zinc binding proteins, 
GATA binding factors, homeodomain transcription factors and zinc fingers kruppel-like 
transcription factors. Although there is no specific study on the expression of these PAX9 
promoter factors on development, the Kruppel-like transcription factor, for instance, was 
shown to be expressed by the mesenchymal cells of first arch at E11.5 (Garrett-Sinha 
1996). The same analysis on MatInspector software revealed the presence of one biding site 
for glucocorticoid responsive and relative elements (core sequence: GTGC) within the 
507bp deleted sequence. DNA sequences from human, dog, mouse, rat and chimpanzee 
were obtained using the Blat Search Genome (http://genome.ucsc.edu/cgi-bin) and aligned 
with the software Clustalw (www.ebi.ac.uk/clustal). The sequence TGTGC (containing the 
glucocorticoid responsive element) is conserved among these species, suggesting that it has 
an active role in the transcriptional regulation of PAX9 gene (Figure 5).  
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Luciferase activity in plasmid PAX9-pGL3B2 was always much weaker than the 
other two constructions used, indicating that sequences present between -1106 and -751 or 
355bp were important for the transcriptional activity of PAX9 promoter. It was showed in 
previous studies that polymorphisms in the promoter region from -1106 to -751 of PAX9 
gene may have an influence on the transcriptional activity of this gene and are associated 
with hypodontia in humans. T-912C polymorphism in the 5’ region of the gene PAX9 
appears to be associated with hypodontia in humans (Peres et al. 2005).  
Concerning the ergocalciferol treatment, a significant reduction (−50%; p ≤ 0.001) 
of luciferase expression compared to the control was observed in all the constructions, 
especially when cells were treated with 10μg/ml. Vitamin D plays an important role in 
tissue mineralization and calcium/phosphate homeostasis during skeletal development 
(Wentz et al 1958, Berdal et al. 1995). Nutritional vitamin D deficiency could cause 
morphogenic abnormalities, matrix disorganization and hypomineralization during tooth 
formation (Zhang X et al. 2007, Papagerakis et al. 1999, Davideau JL et al. 1996). In this 
study, we characterized the transcripitional activity of specific regions of the PAX9 
promoter gene and we demonstrated that ergocalciferol can modulate the transcriptional 
inhibits the promoter activity of PAX9 gene.  
In summary, dexamethasone, retinoic acid and ergocalciferol can regulate the 
transcriptional activity of human PAX9 gene. It is worth to mention that the receptors for 
these drugs may also modulate the transcription of other genes which eventually repress or 
stimulate PAX9 activity. In this study, we observed that deletions of 507 bp (PAX9-
pGL3B3) and 355 bp (PAX9-pGL3B2) have profound effect on the PAX9 gene 
transcription. It will be interesting to examine whether other modifications add further layer 
of complexity to the regulation of transcriptional activity on PAX9 promoter.  
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Figure 5. PAX9 5´ flanking sequences of chimpanzee, dog, mouse, and rat aligned with 
human sequences. DNA sequences were obtained using the Blat Search Genome 
(http://genome.ucsc.edu/cgi-bin) and aligned with the software Clustalw 
(www.ebi.ac.uk/clustalw). Conserved consensus sequences are underlined by asterisk (*). 
Four regions with 4 consecutive conserved bases are marked inside squares: binding sites to 
GGGA, ATTT, CAAC and GTGC transcription factors. Biding site for glucocorticoid 
responsive and relative elements (GTGC) is shown to be conserved among species. 
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ABSTRACT 
 Pax genes play important roles in mammalian development and organogenesis. 
Pax9, a member of this transcription factor family, is expressed in somites, pharyngeal 
pouches, mesenchyme involved in craniofacial, tooth, and limb development, as well as 
other sites during mouse embryogenesis. The aim of this work was to determine changes in 
PAX9 expression under dexamethasone (DEX), retinoic acid (RE) and ergocalciferol 
(VITD2) treatment and observe their influence in the transcriptional activity of this gene. 
Our results have showed that PAX9-pGL3B1 and PAX9-pGL3B2 promoter activity was 
increased by the treatment of 1μg/ml of dexamethasone and ergocalciferol; 10μg/ml of the 
same reagents decreased this activity. Retinoic acid and dexamethasone did not altered 
PAX9-pGL3B3 (−1106 to +92, 507bp deleted with ApaI digest) behavior. This result 
suggests that 507bp deletion or sequence between -645 to -138 is important for the 
transcriptional activity of PAX9 gene.  In conclusion, we suggest that 507bp region within 
PAX9 promoter in PAX9-pGL3B3 may contain biding sites that are responsive for retinoic 
acid and dexamethasone since none of concentrations of this reagent influenced change in 
promoter activity. 
 
 
Keywords: PAX9 promoter gene, Transcriptional activity, pGL3 Basic Vector, Luciferase 
Assays, Mouse odontoblast like cell line MDPC-23. 
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INTRODUCTION 
 
Pax9 is a member of a transcription factor family that is characterized by a common 
motif, the DNA-binding paired domain encoded by the paired box; a conserved DNA 
region originally identified in Drosophila (Bopp et al. 1986, Baumgartner et al. 1987). The 
Pax9 gene is present in all vertebrates analyzed so far, including zebrafish, chick, mouse, 
and man (Stapleton et al. 1993, Neubüser et al. 1995, Nornes et al. 1996) and during mouse 
development is widely expressed in neural crest-derived mesenchyme involved in 
craniofacial and tooth development (Deutsch et al. 1988, Timmons et al. 1994, Neubüser et 
al. 1995, 1997). Spontaneous as well as targeted mutations in Pax9 gene revealed that it 
performs essential functions during mammalian embryonic development since it is 
observed various craniofacial malformations in the skeleton, palate, digits and teeth 
(Thesleff, 2003, Kapadia et al., 2007 Neubüser A. 1995, Peters et al. 1998, Peters et al. 
1999, Satokata I., 1994). PAX9 mutations in human families cause autosomal dominant 
oligodontia, characterized by the absence of permanent molars and pre-molars (Goldenberg 
et al. 2000, Stockton et al. 2000, Nieminen et al. 2001). 
Furthermore, PAX9 is required for secondary palate development and certain 
teratogens such as retinoic acid have been identified as inducers of a cleft secondary palate 
(Sulik et al. 1988, Gorlin et al. 1990). It is believed that retinoic acid functions determining 
position along embryonic anterior/posterior axis in chordates. It acts through homeobox 
genes, which ultimately control anterior/posterior patterning in early developmental stages 
binding to retinoic acid response elements in the regulatory regions of direct homeobox 
genes targets, thereby activating gene transcription directly (Holland LZ, 2007). Retinoic 
acid has effects on the fundamental process of morphogenesis and on the growth and 
differentiation of normal and transformed cells.  
Other hormones and vitamins can influence embryologic development. Vitamin D 
has been reported to play an important role in tooth mineralization (Wentz et al. 1958, 
Berdal et al. 1995, Zhang X et al. 2007, Papagerakis et al. 1999, Davideau JL et al. 1996). 
Corticosteroids are involved in a wide range of physiologic systems and glucocorticoid 
hormones also control gene transcription by activating glucocorticoid receptor response 
elements in the regulatory region (Wu W et al. 2005) and may influence the expression of 
genes related with odontogenesis.  
Considering that a great variety of physiological or pharmacological environmental 
stimulus may have impact on transcriptional regulation of genes, this study focused on the 
analysis of the 5’ region of the PAX9 gene that may be mediated by the effect of 
dexamethasone, retinoic acid and ergocalciferol on PAX9 promoter expression in Mouse 
odontoblast like cell line MDPC-23.  
 
MATERIALS AND METHODS 
 
DNA extraction and amplification 
Human genomic DNA from healthy patients was extracted from samples of 
epithelial oral cells collected by mouthwash with dextrose 3% and purified using 8M 
ammonium acetate and 1mM EDTA (Aidar & Line 2007).  Promoter regions between 
positions -1106 to +92 and -751 to +92 were amplified by PCR using primers PAX9 SacI-
HindIII and PAX9 KpnI-HindIII, respectively, designed with Primer3 version 0.2 
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(Massachusetts Institute of Technology, Boston, MA) (Table 1). PCR reactions were 
performed in a total volume of 25 μl containing 20 ng/2 μl genomic DNA, 10 pg of each 
primer, 2.5 μl MgCl2 (25 mM), 2.0 μl dNTP mixture (2.5 mM each), 2.5 μl of 10× reaction 
buffer and 0.2–0.4 unit of thermostable DNA polymerase. DNA was denaturated at 95°C 
for 2 min, followed by 35 cycles of denaturation of 30s at 95°C, annealing for 45s at 60–
64°C, extension of 45–60s at 72°C, and final extension of 10 min at 72°C on GeneAmp 
2400 PCR Thermal Cycler (ABI corporations). Aliquots (5μl) of the PCR product were 
electrophoresed on 1% agarose gels and visualized under UV illumination after staining 
with ethidium bromide.  
 
Generation of promoter constructs 
 
 The PCR products of PAX9 promoter fragment of 1198bp and 843bp upstream in 
the 5’-flanking region of PAX9 gene was generated from genomic DNA of epithelial oral 
cells from healthy patients. The PCR products were cloned in the luciferase reporter 
plasmid using the vector pGL3 Basic. Luciferase reporter recombinant PAX9-pGL3B1 and 
PAX9-pGL3B2 were generated by inserting the promoter fragment into SacI-HindIII and 
KpnI-HindIII sites of pGL3-Basic vector, respectively. The luciferase reporter recombinant 
PAX9-pGLB3 was generated by deleting 507bp from the 1198bp promoter fragment 
already cloned in the vector pGL3-basic using ApaI restriction enzyme. Constructs were 
confirmed by sequencing, cutting with SacI, KpnI, HindIII combined and PCR. The pRL-
TK vector (Promega) contains the reporter Renilla luciferase gene was used as a control to 
correct variations in transfection efficiency. The constructs are shown in Figure 1. 
 
 
Fragment Forward primer (5´ - 3´) Reverse primer (5´- 3´) Product 
Size 
PAX9 
SacI-
HindIII 
CTCGAGGTGTAGAGCTCGCAGC AAGCTTCTAGGTGATTGGTGCGGGTCGGT 1198bp 
PAX9 
KpnI-
HindIII 
TCTGGATTGTCAGGTACCAGTAACAG AAGCTTCTAGGTGATTGGTGCGGGTCGGT 843bp 
Mouse 
18S rRNA   
GAGGTAGTGACGAAAAATAACAAT TTGCCCTCCAATGGATCCT 99bp 
Pax9 
mouse   
CATCCGACCTTGTGACATCA GGTCACTACGACTCCTATAA 336bp 
Table 1. Primers used to amplify regions PAX9 gene promoter for cloning (restriction sites 
of enzymes SacI, KpnI and Hind III in italic) and Primers used for Pax9 and 18S RT-PCR 
amplification. 
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Figure 1. Schematic diagram of promoter constructs. 1) PAX9-pGL3B1 construct clone 
PAX9 gene promoter 1198bp from −1106 upstream to +92 downstream of translation start 
site (ATG). 2) PAX9-pGL3B2 construct clone PAX9 gene promoter 843bp from −751 
upstream of translation start site (ATG) to +92 downstream of translation start site (ATG). 
3) PAX9-pGLB3 construct clone PAX9 gene promoter 691bp from −1106 upstream of 
translation start site (ATG) to +92 downstream of translation start site (ATG) using deletion 
of 507bp in restriction sites (-645 and -138) of ApaI enzyme.  
DNA sequencing 
 
In order to confirm cloning assays, samples of constructions were subjected to 
automatic sequencing in 20 μl containing 1 μl of DNA, 3 μM of sense primer and 8 μl of 
Big Dye Terminator Ready v.2.0 (Applied Biosystems, Foster city, CA, USA). The cycle 
sequencing product was then run through an ABI 3739 automated sequencer (Perkin Elmer, 
Applied Biosystems, USA) according to the manufacturer´s protocol. The screening of the 
sequence was performed by comparing the output nucleotide sequence with published 
sequence of the PAX9 gene (GenBank database) using Clustawl and naked eye check by 
Bioedit sequence alignment Editor Software/version 7.0.5.3. The potential biding sites were 
selected by the promoter transcription factor biding predict software 
(www.genomatix.de;www.gene-regulation.com).  
 
 
 
Culture cells and reagent treatments 
 
 Mouse odontoblast like cell line MDPC-23 were generously provided by Dr. Zoltan 
Tokes, University of Southern California (Los Angeles, CA) and cultured according to the 
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suppliers protocol at 37°C humidified atmosphere, 5% CO2 in DMEM (Invitrogen, 
Carlsbad, CA) media supplemented with 5% fetal bovine serum (Invitrogen, Carlsbad, 
CA), 1% penicillin/streptomycin (Invitrogen, Carlsbad, CA). Unless otherwise stated, cells 
were plated at 500,000 cells/10 cm plate. The medium was replaced every 2–3 days. The 
mycoplasma test was done using MycoAlert
®
 Mycoplasma Detection Kit (Lonza).  
  
Chemicals 
 
Dexamethasone (9α-Fluoro-16α methylprednisolone - DEX), All-trans-Retinoic 
acid - RE (tretinoin) and Ergocalciferol (irradiated ergosterol/vitamin D2 - VITD2) (St. 
Louis, MO, USA) were diluted in absolute ethanol at final concentration of 10mM as stock 
solution. Approximately 5 x 10
4
 to 1 x 10
5
 MDPC23 cells was maintained in 12-well 
culture plates and exposed in triplicate to reagents at concentrations of 0.1 μg/ml, 1μg/ml, 
or 10μg/ml, to ethanol 100% (vehicle control added to untreated samples) 48 hrs prior to 
mRNA extraction, according to conditions previously described (Antonova L. and Mueller 
C. 2008). 
 
Reverse transcription and Real-time PCR 
 
Total RNA was harvest from cells and purified using the Aurum Total RNA mini 
kit (BioRad Hercules, CA), following the manufacturer’s recommendation. RNA was 
quantified and the quality tested by photometric measurement. We only used highly 
purified RNA (A260/A280>1.95). cDNA was synthesized from 3μg total RNA using the 
kit High capacity archive cDNA (Applied Biosystems, Carlsbad, CA). The selected specific 
and optimal sequences of primers 18S rRNA and Pax9 mouse, shown in Table 1, were 
chosen to prevent amplification of genomic DNA. Real time PCRs in triplicate were carried 
out in a final volume of 25μl, containing 1 μM of primers, 1x Syber Green supermix (Bio-
Rad), and variable amounts of RT products. Thermal cycling was peformed in DNA Engine 
Opticon real-time PCR detection system (PTC-200 DNA Engine Cycler and CFD-3200 
Opticon Detector) from BioRad. Data were treated with the accompanying software 
analysis with melting curve. The program profile used for Pax9 mouse amplification was: 
95˚C for 3 min and 50 cycles of denaturation for 20 seconds at 95˚C, and annealing for 15 
seconds at 58˚C and extension for 30 seconds at 72˚C. The program profile used for 18S 
rRNA was 94˚C for 3 min followed by 30 cycles of denaturation, annealing and extension 
for 30 sec each at 94˚C, 67.5˚C and 72˚C, respectively. 
 
 
 
Transient transfections and Dual luciferase assay system 
 
MDPC23 cells (3 x 10
5
 cells/well) were plated in 12-well plates
 
and incubated for 3 
days. On the third day (cells reached 80%-90% of confluence), the culture medium was 
aspirated, and the cell monolayer was washed with pre-warmed sterile PBS and trypsinazed 
with 1x Trypsin-EDTA (0.05% trypsin EDTAo4Na) (Invitrogen, Carlsbad, CA). Cells were 
tranfected by eletroporation using Electro Square Porator ECM830 (BTX, CA) according to 
the manufacturer’s instructions (240V with a single 25-ms pulse) with 4000ng of pGL3-
basic promoter constructs PAX9-pGL3B1, PAX9-pGL3B2 and PAX9-pGL3B3 encoding a 
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firefly luciferase gene (pGL3-basic vector) and co-transfected with 300ng of pRL-TK 
(Promega, USA) encoding the Renilla luciferase gene. The Cells were kept under triplicate 
treatment of concentrations of 10μg/ml, 1μg/ml and 0μg/ml for each reagent 
(Dexamethasone, Retinoic acid and Ergocalciferol) for 48 hours. Then cells were lysed 
with the passive lysis
 
buffer (Promega, Madison, WI) and assayed in triplicate for luciferase 
activity on a 1420 Multilabel Counter Victor
3
 V plate reader (Perkin-Elmer, Turku, 
Finland) using the Dual-Luciferase Assay System (Promega) according to the 
manufacturer’s instructions. Promoter activities were expressed as a ratio of firefly 
luciferase to Renilla luciferase luminescence in each well.  
Trypan blue assays 
 
Cell viability was determined by trypan blue assays testing whether dexamethasone, 
retinoic acid and ergocalciferol challenged cells. Trypan blue assays were performed as 
previously described by Lissy 2000 and Devireddy 2001. In brief, cells were harvested by 
brief trypsinization 24 h after the addition of dexamethasone, retinoic acid and 
ergocalciferol (Sigma). Both floating and attached cells were assayed. At least 150 cells per 
treatment were counted after being stained with trypan blue at a final concentration of 
0.2%. Assays were performed in duplicate in tree independent experiments. 
 
Statistical analysis 
 
With respect to Real-time PCR Pax9 gene expression analysis, an inter-group 
analysis was performed using nonparametric Kruskal–Wallis test at the level of 5%, 
followed by Dunn’s test when differences were detected. Sample means and standard 
deviations were calculated for the luciferase assays which were performed in triplicate. 
Individual experiments were carried out at least three times and a representative experiment 
is shown. Statistical analysis calculations for luciferase assay results were performed using 
the two-sample Student’s t-test function assuming equal variances. The values of p ≤ 0.05 
were regarded as significant. 
 
 
RESULTS 
 
Pax9 mRNA expression in MDPC23 under DEX, RE and VITD2 treatment 
  
In order to assess the effect of various drugs on Pax9 mRNA expression in 
MDPC23 cells, cells were treated with various concentrations of dexamethasone, retinoic 
acid and ergocalciferol for 48 hours. Figure 2 shows that 1ug/ml of dexamethasone and 
retinoic acid decreased expression of the Pax9 gene in MDPC23 cell in 12% and 7%, 
respectively (*p<0.001). Ergocalciferol treatment promoted a 47% to 51% increase the 
mRNA expression of Pax9. 
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Figure 2. The influence of various concentrations of Dexamethasone, Retinoic Acid and 
Ergocalciferol in the expression of Pax9 mRNA expression in MDPC23 cells. Exposure 
time 48 hrs. Control=100% ethanol. Data presented as mean values ± SD (n=4). *p≤0.001. 
 
PAX9-pGL3B1, PAX9-pGL3B2 and PAX9-pGL3B3 construct confirmation 
 
 In total, we combined tree specific sequences of the promoter region of human 
PAX9 gene with the pGL3-basic vector encoding a firefly luciferase gene (PAX9-pGL3B1-
from −1106 to +92, PAX9-pGL3B2-from −751 to +92 and PAX9-pGLB3-from −1106 to 
+92 with deletion of 507bp), which were confirmed by sequencing, restriction enzyme 
cutting and PCR (data not shown).  
 
 
 
 
Transcriptional activity of PAX9 promoter in MDPC23 under reagent treatment 
 
To examine the transcriptional activity of the PAX9 gene promoter, 1198bp (-1106 
to +92), 843bp (-751 to +92) and 691bp (deletion of 507bp from region -1106 to +92) 
fragments were placed in the upstream of the firefly luciferase gene in the pGL3-Basic 
vector. The resultant plasmid PAX9-pGL3B1, PAX9-pGL3B2 and PAX9-pGL3B3 were 
transiently transfected into the MDPC23 cells that were treated with various concentrations 
of dexamethasone - DEX, retinoic acid – RE and ergocalciferol – VITD2 for 48 hours. 
Then, the firefly luciferase activity obtained was compared with those from the pRL-TK-
control plasmid. In figure 3A and 3C, PAX9-pGL3B1 and PAX9-pGL3B2 lucifarase 
activity was increased by the treatment of 1μg/ml of dexamethasone and ergocalciferol in 
16 to 19%; 10μg/ml of the same reagents decreased this activity in 23 to 35% (p≤0.001). 
Under retinoic acid treatment, the luciferase activity of PAX9-pGL3B1 was increased with 
1μg/ml in 65% and decreased with 10μg/ml in 23%, but for the PAX9-pGL3B2, 
concentrations of 1μg/ml and 10μg/ml increased the promoter activity in 98% and 39%, 
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respectively (Figure 3B). For the PAX9-pGL3B3 construction, 1μg/ml and 10μg/ml of 
ergocalciferol promoted decrease in the luciferase activity in 65% (p<0.005) while 
dexamethasone and retinoic acid treatment did not alter luciferase activity (Figure 3C). 
Figure 3. Functional analysis of PAX9 gene promoter by the Dual luciferase assay in 
MDPC23 cells. Luciferase activity in MDPC23 cells transfected with PAX9-pGL3B1, 
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PAX9-pGL3B2, PAX9-pGL3B3 and pRL-TK as a control under Dexamethasone (DEX) 
(3A), Retinoic Acid (RE) (3B) and Ergocalciferol (VITD2) (3C) treatment. 
 
DISCUSSION 
 
In this study, the results obtained with the RT-PCR experiments showed that 
ergocalciferol promoted a significant concentration-dependent increase in the expression of 
Pax9 in concentrations of 10μg/ml, 1μg/ml and 0.1μg/ml in mouse odontoblast like cell line 
MDPC-23. Vitamin D plays an essential role in a variety of biological events such as 
calcium homeostasis, bone formation-metabolism and cellular differentiation (Bouillon et 
al.1995; Walters, 1992; Chen & DeLuca, 1995). Hormonal form of vitamin D acts as a 
ligand for the vitamin D receptor (VDR), and VDR–vitamin D complex activates the target 
gene expression at the trancriptional level (Freedman, 1999, Demay et al., 2006). Data 
obtained in this study shows that Pax9 expression in odontoblast like cell line was 
responsive to vitamin D2 treatment. It is known that cells devoted to enamel and dentin 
formation at the bell stage of odontogenesis have express Vitamin D receptor presented in 
both dental epithelial and mesenchymal tissues (Mark et al., 1995) and matrix proteins of 
mineralized tissues, such as osteocalcin, is responsive to vitamin D (Demay et al., 1990; 
Ozono et al., 1990; Breen et al., 1994). Previous studies in animal model suggest that 
specific dysplasia of rachitic enamel (decrease of intraprismatic enamel) is secondary to 
vitamin D dysregulation of amelogenin expression (Papagerakis et al., 1999).  
In the luciferase assays, we observed that luciferase activity was increased by lower 
concentrations (10ug/ml) of dexamethasone, ergocalciferol and acid retinoic in constructs 
PAX9-pGL3B1 (−1106 to +92) and PAX9-pGL3B2 (−751 to +92) whereas higher 
concentration (10ug/ml) inhibits promoter activity of these constructions. It is interesting to 
observe that there is a pattern followed all constructions since all greatly responded with 
1ug/ml of reagents but inhibited with 10ug/ml. Different from PAX9-pGL3B1 and PAX9-
pGL3B2 constructions, retinoic acid and dexamethasone did not altered PAX9-pGL3B3 
(−1106 to +92, 507bp deleted with ApaI digest) behavior. This result suggests that 507bp 
deletion or -645 to -138 of this construct contains biding sites for retinoic acid and 
dexamethasone receptors. The analysis of the DNA biding sites on MatInspector software 
(http://www.genomatix.de/cgi-bin/eldorado/main.pl) revealed that the region of 507bp 
removed from the construction PAX9-pGL3B3 is located within various core binding 
sequences, such as, Kruppel-like transcription factors. This transcription factor was shown 
to be expressed by the mesenchymal cells of first arch at E11.5 and thereby, may have an 
important role in development (Garrett-Sinha et al. 1996). The same analysis on 
MatInspector software demonstrated that there are biding sites for glucocorticoid 
responsive and relative elements in this 507bp deleted sequence, explaining why the 
promoter activity in this construction was also not altered with dexamethasone treatment. 
Moreover, DNA sequences were obtained using the Blat Search Genome 
(http://genome.ucsc.edu/cgi-bin) and aligned with the software Clustalw 
(www.ebi.ac.uk/clustal ) showed that this 507bp region was well conserved in evolution, in 
chimpanzee, dog, rat and mouse sequences; suggesting that this region may have an 
important role on the transcriptional regulation of PAX9 gene.  
RT-PCR and Luciferase assays results were different from each other. All 
concentrations of ergocalciferol increased the expression of the gene in the RT-PCR and 
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the same concentrations decreased this expression of the PAX9-pGL3B3 promoter in the 
luciferase assays. Ergocalciferol appears to act at the transcriptional level of the PAX9 to 
reducing expression and activity of the promoter in pGL3 vector. In culture cells the same 
gene expression may have influence of other environmental factors. 
In conclusion, dexamethasone, retinoic acid and ergocalciferol may affect the 
transcriptional activity of transcription factor and also interact with other genes modulating 
the transcriptional activity of PAX9 gene promoter. We observed that 507bp deleted in 
PAX9-pGL3B3 and 355bp deleted in PAX9-pGL3B2 may contain biding sites for 
dexamethasone, retinoic acid and ergocalciferol and may have effect on the PAX9 gene 
function. 
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CONCLUSÃO 
 Verificamos com este estudo que drogas como a dexametasona, ácido retinóico e 
vitamina D podem atuar como moduladores da expressão gênica do gene PAX9 tanto em 
células humanas quanto de camundongo. E ainda, os resultados mostram que a região 
promotora do gene PAX9 humano estudada entre -1106 a +92 possui receptores de ligação 
que podem ser influenciados pelas drogas usadas neste estudo. Mostrou-se também que as 
sequências deletadas do promotor -1106 a -751 e -645 a -138 nas construções PAX9-
pGL3B2 e PAX9-pGL3B3, respectivamente, são de importante relevância na regulação da 
atividade transcricional deste gene. Verificamos que a região correspondente a 507 pb 
deletada do promotor na construção PAX9-pGL3B3 contém sítios de ligação para proteínas 
que são influenciadas por estas drogas. Estes resultados observados com o ensaio da 
luciferase e o PCR quantitativo vem a acrescentar novo entendimento da expressão do gene 
PAX9 in vivo. 
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Abstract 
Pax9 belongs to a transcriptional factor genes family named Pax family. This gene 
is expressed in embryonic tissues like somites, pharyngeal pouch endoderm, distal limb 
buds and neural crest-derived mesenchyme. Some polymorphisms in the upstream 
promoter region of the human Pax9 have been associated with human non-syndromic forms 
of autosomal dominant tooth agenesis. In the present study, we verified the in vitro 
expression of this gene and the influence of two promoter sequences in Pax9 gene, in 
embryo tissues obtained from digits, face and midbrain and hindbrain regions. These 
fragments were cloned into reporter plasmid and were transfected into the different cells 
cultures. Our semi-quantitative RT-PCR results showed that in vitro E13.5 limb bud and 
CNS cells express Pax9, but not in derived facial region cells. Moreover, the luciferase 
assay showed that this protein activity of the constructed vector by themselves were weaker 
than pgl3-Basic alone, suggesting that they are not sufficient to drive Pax9 gene 
transcription. 
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Introduction 
The gene PAX9 belongs to a family composed of nine genes that encode transcription 
factor proteins, the Pax proteins, characterized by the presence of the paired domain, and a 
highly conserved DNA binding region of about 128 amino acids 
1, 2
. These factors play 
important roles in embryonic patterning and organogenesis being expressed in various 
embryonic tissues like somites, pharyngeal pouch endoderm, distal limb buds and neural 
crest-derived mesenchyme that develop into craniofacial structures, like teeth, expressed in 
the mesenchyme of developing tooth germs, especially at the bud and cap 
8, 11, 
and are 
essential during later stages of tooth development 
2, 5, 9, 12
. It is known that they are under 
the control of Fgf/Bmp signaling
 4
. 
Pax9 protein products are essential for the establishment of the odontogenic potential 
of the mesenchyme, where the expression seems to be a marker for the sites of tooth 
formation due to its occurrence before any morphological manifestation of this process 
9
. 
Analysis of mouse embryos showed that the Pax9 is an early marker of tooth development, 
appearing at E10 stage in the mesenchyme, before the ectodermal thickening and prior to 
the expression of other tooth signaling genes. High levels of Pax9 expression are 
subsequently maintained throughout the initiation (E11.5), bud, and cap stages and  down 
regulated at the bell stage (E16)
11
.  
The initial description of the tooth agenesis caused by the mutation in Pax9 was made 
by Stockton et al. 
14
, since then, many other autosomal dominant mutations have been 
identified throughout the entire gene, been the majority of mutations is located in the paired 
domain, the DNA-binding domain of PAX9. Polymorphisms in the upstream promoter 
region of the human PAX9 have been associated with variable forms of oligodontia 
10
. To 
date, it is known that heterozygous deletion of whole PAX9 gene is associated with a 
severe form of non-syndromic tooth agenesis that involves all the primary molars and some 
posterior permanent teeth (premolars and molars) 
3, 5, 6, 14
. However, the precise 
mechanisms for the development of tooth agenesis remain unclear 
17
. 
The aim of the present study is to verify the influence of promoter sequences in the 
transcription of PAX9 gene. Two fragments of the promoter region were cloned into 
reporter plasmid containing luciferase gene and transfected into three different rat embryo 
tissues: digits, face and midbrain and hindbrain regions.  
 
Material and Methods 
Construction of Expression Plasmids - The PAX9 promoter region between positions 
– 1209 and +92 was amplified from human DNA by PCR and subcloned into SacI-HindIII 
restriction sites of TOPO TA vector (Invitrogen) to generate high copies for cloning into 
pGL3-Basic vector. The second plasmid was constructed by the pGL3-Basic-PAX9 
promoter digested with ApaI restriction enzyme, resulting on an insert with 590 bp (pGL3-
Basic-PAX9-ApaI). In both, the +92 base was oriented to luciferase gene (fig. 1).  
Maternal and Fetal Surgical Manipulation - The day of sperm found is E0, and at 
day 13.5 pregnant females was anesthetized with Ketamine (100mg/ml) and after the 
surgery, it was killed by cervical dislocation and the uterus was aseptically removed out 
into a 25ml screw-capped tube containing 20ml Phosphate-Buffered Saline (PBS) and 1% 
antibiotic solution (Anti/Anti Invitrogen). Embryos were dissected out the uteri in a flow 
hood area and transferred to a fresh dish of sterile PBS. The embryos digits, face and 
midbrain and hindbrain regions (these cells will be referred as CNS) were placed in 35mm 
cell culture dishes. Experiments were performed in duplicate. The cells were grown in 
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Dulbecco's Modified Eagle's Medium DMEM – High glucose (Invitrogen) supplemented 
with 10% fetal bovine serum and 1% antibiotic solution (Anti/Anti - Invitrogen) and 
incubated at 37 ° C in the presence of 5% CO2. Ethical approval was granted by the Ethics 
Committee of the Piracicaba Dental School.  
mRNA analysis - After 48 hours of culture, cells were homogenized and total RNA 
were isolated with TRIzol™, following manufacturer’s instructions (Invitrogen). The 
cDNA was synthesized from 1g of total RNA using Superscript III Reverse Transcriptase 
following manufacturer’s instructions (Invitrogen). DNase I digestion of RNA was 
performed prior to the reverse transcriptase reaction. In two independent experiments, PCR 
amplifications were performed using gene-specific primers for Pax9 and β-actin genes. 
Pax9 primer sequences were: Pax9Rat 5’ (GAGTTCCATCAGCCGGATTC) and Pax9Rat 
3’ (CAAGGCTCCCTTCTCCAATC). Polymerase chain reactions were performed on a 
TC-512 PCR machine (Techne Incorporated Burlington, NJ, USA) using 5L of cDNA, 5 
pmoles of each oligonuclotides primers, GoTaq
®
 Green Master (Promega) in a 25 μL 
volume. The PCR program initially started with a 94
o
C denaturation for 4 min, followed by 
40 cycles of 94
o
C for 1 min, 50
o
C for 1 min, 72
o
C for 1 min and a final extension of 72
o
C 
for 10 minutes for all set of RT-PCR primers. β-actin gene amplifications were performed 
in separated tubes. PCR program initially started with a 94
o
C denaturation for 4 min, 
followed by 40 cycles of 94
o
C for 1 min, 55
o
C for 1 min, 72
o
C for 1 min and a final 
extension of 72
o
C for 10 minutes. Amplifications were verified in 2% agarose gels stained 
with ethidium bromide [10 μg/ml] and photographed on top of a 280 nm UV light box. The 
gel images were digitally captured with a CCD camera and analyzed with the NIH Image J 
program. 
Transient transfection - Transient transfections were performed when 90-95% of 
confluence was reached through lipofection by using Lipofectamine 2000™ reagent 
(Invitrogen) in the presence of Reduced Serum Medium according to the manufacturer’s 
instructions. 0.8 µg of pGL3 (Promega™) was used for a co-transfection with 0.08 µg of 
the pRc-CMV vector (kindly provided by Dr. Kleber Franchini - Unicamp) for luciferase 
analysis normalization. Transfected cells were incubated at 37°C in the presence of 5% 
CO2.  
Luciferase analysis - Forty eight hours after the transfection, cell extracts were 
collected and firefly and Renilla luciferase activities were measured (dual glo luciferase 
assay system; Promega™). Briefly, 75L of remain DMEM serum free medium were 
mixtured with 75uL of Dual-Glo™ Luciferase Reagent and incubated for 1 min. The lysate 
were measured for firefly luciferase activity in 96-well microplate reading luminometer 
(Veritas
™
- Turner Biosystems). Each sample was normalized to Renilla luciferase 
absorbance to correct for variations in transfection efficiency using 75L of Stop & Glo® 
Reagent added to the same well and incubated for 10 min after reading. Experiments were 
performed in duplicate. 
 
Results 
mRNA analysis - In our experiments, a semi-quantitative assay RT-PCR was 
performed to measure the in vitro expression of the gene Pax9, using E13.5 rat embryonic 
cell in culture. The results indicated that the Pax9 gene is not expressed in face at this day, 
while in digits and CNS this gene is expressed (figure 2). The presence of amplicons for the 
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amplification of ß-actin gene validates our approach, indicating that the gene is repressed in 
face tissues of the evaluated embryos.  
Luciferase analysis – The experiments revealed that both transfected constructions 
pGL3/Pax9 plasmids were not able to highly express the Luc protein. However, values of 
expression were found in decreasing the protein synthesis in digits and CNS transfected 
cells, and inhibited it in face transfected cells (figure 3). 
 
Discussion 
In this study, Pax9 transcriptional regulatory pattern was examined by analysis of its 
promoter sequence in rat embryos. In our experiments semi-quantitative RT-PCR was 
performed to detect gene expression of Pax9 in vitro by using rat embryonic cell. We also 
analyzed the capacity of Pax9 promoter region to drive the transcriptional activity by 
transfecting pGL3 basic plasmids vectors containing inserts of Pax9 promoter region in rat 
embryos primary cell culture of digits, face and CNS.   
Experiments showed that Pax9 gene were expressed in day E13.5 in limb bud and 
CNS cells, but surprisingly was not expressed in cells derived from facial region. 
Kriangkrai et al 
7
 showed that Pax9 was expressed on facial region of rats at stages E13 and 
E14. One possible explanation for this discrepancy is that the transcription of PAX9 was 
inhibited when facial cells were cultured. In fact, one thing that is evidenced in studies that 
analyze the expression of PAX9 in mouse and rat embryonic tissues is that the expression 
of this gene changes rapidly during ontogeny 
7, 9
. Therefore, it is conceivable PAX9 
transcription may be influenced subtle changes in cell environment. In the present study 
two polymorphisms in the PAX9 promoter located within the region, shown to be 
associated with third molar agenesis in humans, were analyzed 
15
. Moreover, two conserved 
non-coding regions with enhancer activities for expression of Pax9 were already identified, 
where one of these sequences contained a consensus Gli-binding motif 
13
. In addition, those 
authors also identified highly conserved sequences in the 5’ regions of Pax9 gene that were 
located about 2kb distant from the transcription initiation site and in the third intron of this 
gene. 
 
Conclusions  
The results of the present study showed that the luciferase activity of pGL3-Pax9 
constructs were weaker than pGL3-Basic vector alone, suggesting that PAX9 5’ flanking 
sequences alone are not sufficient to drive Pax9 gene transcription and that this region 
might contain inhibitory cis-acting sequences. These results also indicate that enhancer 
sequences located in 5’ sequences distant from the transcription origin or in intronic regions 
are necessary for Pax9 transcription. 
 
 
 
 
 
 
 
 39 
Legends 
Inserto
1098pb
Corte 
Sítio 
413
Corte 
Sítio 921
Deleção com ApaI: 
remoção de 508pb 
Inserto
590pb
 
ApaI G-GGCC’C  -  2 Cortes: local 413 e 921 – Coesivo 
         C’CCGG-C 
Figure 1: Construct Pgl3Pax9/ApaI (-1106 to + 92) was digested with ApaI and re-ligated 
resulting in a plasmid containing the 590bp (by Ramenzoni, L.L.). 
 
Figure 2: Pax9 expression in rat embryos cells were detected by semi-quantitative PCR in 
2% agarose with ethidium bromide. 
 
Figure 3: Luciferase expression and inhibition evidences in rat embryo 13.5 days of digits, 
face and CNS cells cultures. It can be observed that in the digits and CNS cells, the Luc 
was down expressed in pGL3Pax9SacI transfected cells, and its complete inhibition in 
pGL3B+ Inserto de 1098pb pGL3B+ Inserto 590pb após deleção e 
ligação  
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pGL3Pax9ApaI transfected cells. In face cells, there was the complete inhibition of the Luc 
expression of all plasmids transfected cells.   
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ANEXO 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
